Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 with Concurrent TACE in Unresectable HCC
NCT02006030Phase 2Completed
- Sponsor
- Polaris Group
- Start
- Oct 2014
- Primary completion
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Pegargiminase in hepatocellular carcinoma (HCC), sponsored by Polaris Group. Started Oct 2014; status: completed.
02
Drugs
Pegargiminase
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02006030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02006030.